Hongmei Sun

机构：Shandong University of Science and Technology · ORCID：0000-0003-1383-5720

发表论文 24 篇 · 总被引 457 次 · h-index 10

代表论文

• Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study (2024 · Journal of Clinical Oncology · 被引 214)
• Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review (2019 · Frontiers in Pharmacology · 被引 74)
• Medialization thyroplasty versus injection laryngoplasty: A cost minimization analysis (2017 · Journal of Otolaryngology - Head and Neck Surgery · 被引 29)
• First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial (2025 · 癌症：英文版 · 被引 21)
• Incentivizing at‐risk production capacity building for COVID‐19 vaccines (2021 · Production and Operations Management · 被引 20)
• SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial. (2024 · Journal of Clinical Oncology · 被引 16)